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Abstract
Background: Parkinson’s disease (PD) is characterized at the cellular level by a destruction of neuromelanin (NM)-
containing dopaminergic cells and a profound reduction in striatal dopamine. It has been shown recently that anti-
melanin antibodies are increased in sera of Parkinson patients, suggesting that NM may act as an autoantigen. In
this study we tested whether NM is being recognized by dendritic cells (DCs), the major cell type for inducing T-
and B-cell responses in vivo. This recognition of NM by DCs is a prerequisite to trigger an adaptive autoimmune
response directed against NM-associated structures.
Results: Murine DCs were treated with NM of substantia nigra (SN) from human subjects or with synthetic
dopamine melanin (DAM). DCs effectively phagocytized NM and subsequently developed a mature phenotype
(CD86high/MHCIIhigh). NM-activated DCs secreted the proinflammatory cytokines IL-6 and TNF-a. In addition, they
potently triggered T cell proliferation in a mixed lymphocyte reaction, showing that DC activation was functional
to induce a primary T cell response. In contrast, DAM, which lacks the protein and lipid components of NM but
mimics the dopamine-melanin backbone of NM, had only very little effect on DC phenotype and function.
Conclusions: NM is recognized by DCs in vitro and triggers their maturation. If operative in vivo, this would allow
the DC-mediated transport and presentation of SN antigens to the adaptive immune system, leading to
autoimmmunity in susceptible individuals. Our data provide a rationale for an autoimmune-based pathomechanism
of PD with NM as the initial trigger.
Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder characterized at the cellular level by a
destruction especially of neuromelanin (NM)-containing
dopaminergic cells and a profound reduction in striatal
dopamine. NM accumulates in the cytoplasm of dopa-
minergic neurons starting within the first 3-5 years after
birth [1-3]. NM concentration increases with age and its
optical density has been shown to increase until 60
years of life [4]. In patients with juvenile PD as well as
with idiopathic and MPTP-induced PD, NM also accu-
mulates in the extracellular space of substantia nigra
(SN) [5-7].
Exracellular NM does not behave passively. Both pro-
tective and toxic effects have been reported (reviewed
by Zecca [8,9]). The protective role is most notably
through its ability to trap free radicals and toxins [8].
Toxic effects of NM are mainly due to NM highly-com-
plexed with iron [10,11]. In vitro NM activates microglia
by triggering NK-B activation and the release of the
proinflammatory cytokines TNF-a and IL-6 [12]. When
injected into the brains of rats, human NM triggers neu-
roinflammation and neurodegeneration [13,14], suggest-
ing a proinflammatory role for NM.
The primary etiological factor for PD is still unknown.
Several hypotheses have been proposed [15-18]. Autoim-
mune processes in PD have been suggested previously
[19,20]. Autoantibodies directed at neuronal structures
have been found in sera of PD patients [21-25]. In an
interesting study brains of PD patients exhibited an IgG
binding on dopamine neurons, which was positively cor-
related with the number of HLA positive microglia [26].
Moreover, in the same study the low affinity activating
IgG receptor FcgRIII was expressed on cells
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morphologically resembling lymphocytes. In a recent
publication by Double et al., sera from subjects with
clinical PD were found to display significantly enhanced
IgG-levels specific for melanin derived from catechola-
mines, a structural component of NM [16]. Moreover,
complement binding to NM in brains from PD patients
supports the idea of immunologic clearance of NM in
PD [7]. These data suggest the possibility of a specific
autoimmune response against NM in PD patients.
Dendritic cells (DC) are professional antigen-present-
ing cells able to initiate primary T-cell mediated
immune responses [27]. In a so-called immature state
their main function is the uptake and processing of anti-
gens. Once they become activated (either by proinflam-
matory cytokines or pathogens), DCs migrate into the
draining lymph nodes (LN) to present the antigen to
naïve T- and B-cells [27]. If T- or B-cells specific for
this antigen enter the LN, the cells become primed to
exert their effector functions once they re-encounter the
antigen in the peripheral tissue. In contrast, microglia
are tissue-resident cells that are not able to migrate into
lymphoid tissues to start an adaptive immune response.
They are specialized to present antigens to already acti-
vated, infiltrating T-cells. Hence, a de novo initiation of
an adaptive immune response against an immunogen
within the brain requires DC activation, whereas micro-
glia activation is in this context a downstream event in
order to direct the T- and B- cell response to the site
where the antigen is located. DCs are spare in the
healthy CNS. However, they do accumulate in the CNS
parenchyma in neuroinflammation and CNS autoim-
mune disease following monocyte invasion, from which
they differentiate [28-33].
In this study we hypothesize that extracellular NM
may stimulate DC maturation and thereby promote
NM-associated antigen presentation in an autoimmuno-
genic context. This would reflect the initiating step of
an autoagressive activity against antigens from SN.
Therefore, we investigated whether NM can be recog-
nized and taken up by DCs and subsequently explored
the capability of NM to mature/activate these cells phe-
notypically and functionally for T cell activation. Using
synthetic dopamine melanin (DAM), we investigated the
role of the domanine melanin “backbone” found in NM
in DC activation.
Results
Dendritic cells phagocytose NM and DAM
In order to assess whether DCs recognize NM as a
potential antigen we coincubated DCs with NM and stu-
died phagocytosis by differential interference contrast
microscopy. NM was visible as small black granules of
0.5-5 μm size (Figure 1). After 24 hours of co-incuba-
tion with DCs NM colocalized with DCs in the culture
plate (Figure 1). A z-stack analysis revealed that NM
granules were not just attached to the cell surface but
were indeed internalized by DCs (Figure 1D). Similarly,
DCs also phagocytosed DAM (Figure 2).
DCs mature in response to NM
Phagocytosis of NM resulted within 48 h in maturation
of DCs measured by the upregulation of the cell surface
molecules MHCII and CD86. Whereas only 13% of the
DC population displayed a mature phenotype in the
absence of additives in the culture medium, the amount
of mature DCs increased to 66.8% following contact
with NM (Figure 3A, C and 3E; Bonferroni post hoc
test, p < 0.001). DAM triggered comparably lower DC
activation (31.6%) compared to NM (Figure 3B and 3E;
p < 0.001) but still significantly elevated compared to
medium alone (p < 0.01). As a positive control, DCs
were treated with LPS (Figure 3D and 3E), a strong acti-
vator of DCs. LPS-activation in the experiments dis-
played in this manuscript should only be regarded
qualitatively (instead of quantitatively), as the amount of
LPS used in these experiments is in no relation whatso-
ever to the amount of NM or DAM, except for the fact
that it was titrated in order to provoke a response. We
therefore did not apply statistical analysis comparing the
magnitude of the LPS response with other treatments.
NM generates a functional activation of DCs
Following 48 h exposure to NM, DCs released signifi-
cantly higher amounts of proinflammatory cytokines
such as TNF-a and IL-6 compared to cells treated with
medium alone (p < 0.01 and < 0.001, respectively),
demonstrating that NM-triggered DC maturation gener-
ated functional cells (Figure 4A, B). No additional cyto-
kine release compared to cells treated with medium-
alone was detected in cells treated with DAM.
In order to test whether NM-stimulated DCs can acti-
vate T cell proliferation (a necessary event in the trans-
lation of a DC signal into a T cell response), we
performed a mixed lymphocyte reaction (MLR) in which
T cells isolated from allogenic donor mice were cocul-
tured with NM- or DAM-treated DCs. As depicted in
Figure 4C, NM-treated DCs were able to trigger a prolif-
erative T cell response (p < 0.001 compared to
untreated cells). In contrast to the effects triggered by
NM, no T cell proliferation could be detected following
incubation with DAM.
The experiments displayed in Figure 4 not only
demonstrate that NM-triggered DC activation generates
completely functional DCs (cells that are able to migrate
to the lymph nodes and present antigens to T cells and
that also have the capacity to trigger proliferative T cell
responses), but also narrows the number of NM-com-
pounds that could actually be the trigger of it: As
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synthetic DAM, which lacks many of the compounds
found in NM (lipids, proteins) failed to triggered any
cytokine or proliferative response at all, the dopamine
melanine itself is probably not the stimulus for these
events. However, the dopamine melanine “backbone” of
NM could play an important role in efficient uptake of
NM by DCs, as we observed that DAM alone is being
recognized and phagocytosed very efficiently by DCs
(Figure 2).
NM preparations are free of endotoxin contamination
DCs are very sensitive towards LPS (which for this rea-
son was used as a positive control in the experiments
depicted above). In order to exclude a potential endo-
toxin contamination of the DAM and NM preparations
used in our experiments, we tested the DAM- and NM-
suspensions for LPS using a commercially available LAL
assay. No traces of LPS were detected in the DAM- and
NM-suspensions used for our experiments (Figure 5).
Figure 1 Dendritic cells (DC) phagocytose neuromelanin (NM). Cells were cultured for 48 h in the absence (A, C) or presence (B, D) of
neuromelanin (NM) and analyzed by differential interference contrast (DIC) microscopy. A, B: Overview of cultures. C, D: z-stack analysis of a
single DC from bottom to top. Z-stack distances were 0.70-0.80 μm.
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These results suggest that the DC-stimulating effects are
intrinsic for NM and were not caused by a potential
contamination with endotoxin.
Discussion
Our in vitro study shows that a) extracellular NM is
being phagocytosed by DCs and b) NM triggers matura-
tion and functional activation of these cells. If operative
in vivo, this would inevitably cause a transport of extra-
cellular NM from the brain into cervical lymph nodes,
resulting in a presentation of NM to naïve T- and B-
cells in a highly immunogenic context. This may even-
tually lead to the development of an autoimmune dis-
ease directed at NM-associated antigens. Our study
therefore offers a first evidence for a NM-driven autoim-
mune-based pathogenesis of PD with NM as the initial
trigger of a DC-mediated autoantigen presentation.
Although an autoimmune-based pathogenesis of PD
that targets NM has yet to be conclusively demonstrated
in vivo, a number of previous findings can now be put
into a broader perspective: Sera from subjects with clini-
cal PD display enhanced IgG-levels to catecholeamine-
based melanins, the structural basis of the NM present
in the pigmented neurons of the human SN [16], indi-
cating an immune response directed against NM itself.
In line with this, opsonization of NM with C1q - a com-
plement factor involved in the classical complement
pathway that recognizes antigen-bound IgG and IgM -
has been shown on the surface of extracellular NM in
post-mortem brains of PD-patients [7]. Alternatively (or
additionally), DC-phagocytosis of NM loaded with resi-
dent peptides or proteins (the high affinity of NM to
peptides has been shown before [34]) may initiate the
presentation of formerly-unrecognized autoantigens to
T- and B-cells in a “Trojan Horse way”, triggering an
adaptive autoimmune response directed at proteins
primarily unrelated to NM. In this regard Orr et al.
found in post-mortem sections from PD patients - but
not from age-matched controls - IgG antibodies directed
at pigmented dopamine neurons and auto-IgG binding
colocalized with immunostaining for Lewy bodies [26].
Mature DCs loaded with autoantigens have been
shown to be able to induce autoimmunity against the
loaded antigen in mice [35]. Although DCs seem to be
rare in the healthy brain, myeloid-derived DCs infiltrate
the brain during neuroinflammation [28-33] so that DCs
are likely to encounter extracellular NM also in vivo.
Our data indicate that the DC-activating properties of
NM are conferred by its peptide or lipid components
(but not by the dopamine melanine backbone).
Although the primary repertoire of endogenous lipids
and peptides is unlikely to be able to activate DCs, oxi-
dative modifications of endogenous molecules are being
discussed to confer DC-maturating activity by an
“altered-self” mechanism [36]. Such DC-maturating
activity has already been described for oxidized lipopho-
sphatidylcholine (LPC) found in low-density lipoprotein
(LDL), which potently triggers DC maturation and acti-
vation [37,38]. In a similar way, oxidized protein or lipid
contents of NM could have triggered DC maturation in
our assay system. In line with this, post-mortem studies
with brains from PD patients revealed increased lipid-
peroxidation in SN [10,39].
Our findings that NM activates DCs are in line with
previous reports that NM can activate microglia both in
vitro [14] and in vivo when injected into the rat brain
[13,14]. Microglia and DCs are both myeloid antigen
presenting cells that are closely related, albeit they fulfill
completely different but also cooperative functions dur-
ing an immune response. Whereas activated DCs will
leave the tissue and transport the antigen to the lymph
nodes in order to initiate an adaptive immune response,
Figure 2 Dendritic cells (DC) phagocytose synthetic dopamine melanin (DAM). Cells were cultured for 48 h in the absence (A) or presence
(B) of DAM. Differential interference contrast (DIC) microscopy with z-stack analysis of DCs from bottom to top. Z-stack distances were 1.5 μm.
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activated microglia reside in the tissue and present the
antigen to DC-primed infiltrating T cells in order to
direct the immune response to the tissue in which the
antigen was found. Therefore, combining the results of
the former study on microglia with our results opens a
new autoimmune scenario: NM not only causes local
inflammation (activation of microglia) but may also trig-
ger an adaptive immune response directed at NM itself
via activation of DCs. Our findings therefore add a
potential third characteristic to NM in relation to PD:
whereas NM has previously been discussed to be either
neuroprotective or neurotoxic (and the inflammatory
activity of NM on microglia would be a neurotoxic
characteristic in the broadest sense) our findings suggest
that it might also be considered as an initial trigger for
an adaptive autoimmune response.
Figure 3 Neuromelanin triggers dendritic cell (DC) maturation. Flow cytometric analysis of DC maturation by staining with anti-CD86/anti-
MHCII antibodies. A: medium-treated DCs (untreated). B: DAM-treated DCs. C: NM-treated DCs. D: positive control (LPS-treated DCs). A-D:
representative experiments from triplicates. E: Illustration of the amount of mature DCs from triplicates (data as mean ± S.E.M.; statistical analysis
with one-way ANOVA using Bonferroni multiple comparison as post test; n.s. = non specific (p > 0.05), * p < 0.05, ** p < 0.01, *** p < 0.001).
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Conclusions
Our data suggest that extracellular NM may be the
initial trigger for an adaptive autoimmune response rele-
vant for PD via activation of DCs. Whatever the antigen
(s) recognized in an autoimmune etiology of PD may be,
our data now offers an explanation for the initial trigger
of the autoimmune response against SN-antigens, i.e.
the activation of DCs by a substance exclusively found
in the affected areas, the NM.
Methods
NM preparation
Human SN tissue was obtained from the “Austrian-
German-Brain-Bank” in Würzburg. The use of post mor-
tem human brain tissue was approved by the Ethics Com-
mittee of the University Clinics of Würzburg. The SN was
dissected from post mortem brains of subjects with no his-
tory of neurological, neurodegenerative or psychiatric dis-
eases within 36 h of death on a cool plate (-15°C). Only
cases with a macroscopically regular pigmentation of the
SN and a post mortem delay of less than 36 h were
selected for preparation. The SN was dissected from trans-
versally cut midbrain slices on a cool plate (-15°C). NM
was isolated according the method previously published
[40]. The prepared NM was resuspended in PBS at a con-
centration of 5 mg/ml by pipetting.
Dopamine melanin (DAM) synthesis
Synthetic dopamine melanin (DAM), a widely used model
of human NM (see for example, [41]) was produced by
incubation for 2 weeks of 1 mM dopamine hydrochloride
with 0.1 mM cupric sulfate pentahydrate in phosphate
buffered saline (pH 7.4). The resulting solid oxidation pro-
duct was then washed in distilled water and centrifuged
four times before being lyophilized. DAM was sonicated in
phosphate-buffered saline to produce a suspension of fine,
homogenous granules at a concentration of 1 mg/ml. All
chemicals were obtained from Sigma-Aldrich, Germany.
Confocal Microscopy
Cells were seeded onto μ-slide VI (ibidi, Germany).
Images were obtained using a Zeiss 510 Meta confocal
Microscope (Zeiss, Germany) with a 63 × objective
(NA1.4). Z-stack analysis was performed with imaging
software SP3.2 (Zeiss, Germany).
Animals
C57BL/6 (Charles River/Wiga, Sulzfeld, Germany) and
BALB/c mice (house bred) were kept under SPF (specific-
pathogen free conditions) in our facilities. 4-12 weeks old
female mice were sacrificed by cervical dislocation in order
to isolate bone marrow and lymph nodes, respectively.
Bone marrow and lymph node isolation
Femurs and tibiae from C57BL/6 mice were removed and
purified from the surrounding muscle tissue by rubbing
with Kleenex tissues. Thereafter intact bones were left in
70% ethanol for 2-5 min for desinfection and washed with
PBS. Then both ends were cut with scissors and the mar-
row was flushed out with PBS using a syringe with 0.45
mm diameter needle. Cell clusters were dissociated by vig-
orous pipetting and cells were washed with PBS. 1-1.5 ×
107 leukocytes were obtained per femur or tibia.
Figure 4 NM-mediated dendritic cell (DC) activation is
functional and independent of the melanin backbone. A, B: DCs
were cultured for 48 h in the presence of medium alone, DAM, NM,
or LPS (positive control). The amount of proinflammatory cytokines
in the cell culture supernatants was determined by ELISA. A: TNF-a.
B: IL-6. C: DCs treated for 48 h with medium alone, DAM, NM or LPS
(positive control) were cocultured with allogenic T cells. A-C: Data
from 2 independent experiments with triplicates and quadruplicates
as mean ± S.E.M.; statistical analysis with one-way ANOVA using
Bonferroni multiple comparison as post test; n.s. = non specific (p >
0.05), * p < 0.05, ** p < 0.01, *** p < 0.001).
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Lymph nodes from BALB/c-mice were removed and a
single cell suspension was prepared by grinding the
lymph nodes between the rough ends of two sterile
slides. The lymphocytes were filtered through a 70 μm
Falcon Cell Strain (BD Biosciences, Germany).
Generation of bone-marrow DCs
DCs were generated from bone marrow of mice as
described previously with some modifications [42].
Briefly, bone marrow cells were cultured in 100 mm
bacteriological petri dishes (Greiner bio-one, Germany)
with R10 (RPMI-1640 supplemented with 10% heat-
inactivated fetal calf serum, penicillin (100 U/ml), strep-
tomycin (100μg/ml), L-glutamin (2 mM), and 2-mecrap-
toethanol (50μM, Sigma-Aldrich, Germany)). All media
components were obtained from PAA, Germany.
At day 0 bone marrow cells were seeded at 3 × 106
cells per dish in 10 ml R10 medium containing 10%
GM-CSF supernatant from a cell line transfected with
the murine GM-CSF gene [43]. At day 3 and 6 another
10 ml R10 medium containing 10% GM-CSF superna-
tant was added to the plates. At day 8 cells were used
for experiments.
Treatment of DCs with NM, DAM and LPS
If not indicated otherwise, DCs were treated for 48 h
with NM, DAM at a final concentration of 50μg/ml or
lipopolysaccharide (LPS) at 1μg/ml (Sigma-Aldrich,
Germany) or left untreated in a 24 well plate with 106
cells/well. NM- and DAM suspensions used in DC sti-
mulation experiments were checked for endotoxin con-
tamination and found negative (cutoff was 0.1 EU/ml;
endpoint chromogenic Limulus Amebocyte Lysate
(LAL) assay, Lonza, Germany).
Flow cytometry
DCs were characterized by flow cytometry. 1 × 105 cells
were stained with fluorochrome-conjugated antibodies
directed at CD86 (coupled to APC) and MHCII
(coupled to PE) (both BD Biosciences, Germany) at pre-
titrated concentrations at 4°C for 60 minutes. Cells were
fixed with 2% formalin and analyzed using a FACSCali-
bur (BD Biosciences, Germany). Cell debris was
excluded from analysis by FSC-SSC gating. Quadrants
were set according to staining patterns with isotype-con-
trol antibodies (all antibodies from BD Biosciences, Ger-
many). Flow cytometry data was analyzed using FlowJo
software (Tree Star Inc., OR, USA).
ELISA
Tumor necrosis factor (TNF)-a and interleukin (IL)-6
concentrations were determined from supernatans of
NM- or LPS-treated or untreated DCs using the respec-
tive OptEIA Kits (BD Biosciences, Germany) according
to the instructions of the manufacturer.
Allogeneic mixed lymphocyte reaction (MLR)
DCs from C57BL/6 mice were treated with NM, LPS or
left untreated for 48 h. At day 3, DCs were coincubated
with lymphocytes isolated from BALB/c lymph nodes in
triplicate cultures (96 well) at 3 × 105 cells/well and a
ratio of 1:1. At day 3, cells were pulsed with 1 μCi/well
[3H]methyl-thymidine (Amersham Biosciences, Switzer-
land) over night for 16 h. The plates were harvested
onto glassfiber filtermats with an Tomtec harvester and
filters counted in a 1450 Microplate Counter (Wallac,
Turku, Finland).
Test of endotoxin contamination
The NM-preparation used for the experiments depicted
in this manuscript was tested for potential contamina-
tion with endotoxin using a chromogenic Limulus ame-
bocytes lysate (LAL) assay according to the instructions
of the manufacturer (Lonza, Germany). Briefly, 50μl of
NM sample (100 μg/ml), LPS standards (0.1-1.0 EU/ml)
or endotoxin-free water were mixed with 100 μl of LAL
and incubated for 10 min at 37°C. Substrate solution
was added and samples were incubated for an additional
6 min at 37°C. Enzyme reaction was stopped with
diluted sulfuric acid and chromogen absorption was
measured in a plate photometer at a wavelength of 405
nm. To account for NM-intrinsic absorption at 405 nm,
Figure 5 Negative test of LPS contamination. The DAM- and
NM-preparations used in this study were tested with an endpoint
chromogenic LAL-assay for LPS contamination at a concentration of
50μg/ml and analyzed at a wavelength of 405 nm. LPS standards
with a concentration range between 0.1-1.0 EU/ml were tested
positive, whereas the DAM and NM-preparations were tested
negative for LPS.
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a turbidity control with 100 μg/ml NM without LAL
(volume compensated with water) was measured and
the value was subtracted from NM-sample absorption at
405 nm.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software for Macintosh (version 4.0 c). Data are
expressed as mean ± S.E.M.. For comparison of values
between different treatment groups, one-way ANOVA
was used together with Bonferroni multiple comparison
as post test; p > 0.05 was regarded as non specific, p <
0.05 was attributed with *, p < 0.01 was attributed with
**, and p < 0.001 was attributed with ***.
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